open access
Progression of a corticotroph tumour during durable medical therapy with osilodrostat in a patient with persistent Cushing’s disease
Affiliations- Department of Internal Medicine, Endocrinology, and Diabetes, Medical University of Warsaw, Warsaw, Poland
- Department of Neurosurgery, Military Institute of Medicine, Warsaw, Poland
open access
Abstract
Not required for Clinical Vignette.
Abstract
Not required for Clinical Vignette.
Keywords
corticotroph tumour progression; Cushing’s disease; osilodrostat
About this articleTitle
Progression of a corticotroph tumour during durable medical therapy with osilodrostat in a patient with persistent Cushing’s disease
Journal
Issue
Article type
Clinical vignette
Pages
346-347
Published online
2023-06-21
Page views
1416
Article views/downloads
394
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2023;74(3):346-347.
Keywords
corticotroph tumour progression
Cushing’s disease
osilodrostat
Authors
Bartłomiej Borawski
Agnieszka Wojciechowska-Luźniak
Grzegorz Zieliński
Przemysław Witek
References (5)- Lacroix A, Feelders RA, Stratakis CA, et al. Cushing's syndrome. Lancet. 2015; 386(9996): 913–927.
- Gadelha M, Bex M, Feelders RA, et al. Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. J Clin Endocrinol Metab. 2022; 107(7): e2882–e2895.
- Witek P, Mehlich A, Stasiewicz A, et al. Osilodrostat - an emerging drug for the medical management of Cushing's disease. Endokrynol Pol. 2022; 73(2): 371–374.
- Fontaine-Sylvestre C, Létourneau-Guillon L, Moumdjian RA, et al. Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing's disease. Pituitary. 2021; 24(2): 207–215.
- Reincke M, Albani A, Assie G, et al. Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations. Eur J Endocrinol. 2021; 184(3): P1–P16.
